title: Reply to the letter to the editor 'Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer' Tannock and Pond.
authors.affiliation: University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA. Electronic address: hrugo@medicine.ucsf.edu.
authors.forename: H S
authors.initials: HS
authors.lastname: Rugo
authors.affiliation: Institut Multidisciplinaire D'Oncologie, Genolier, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Aapro
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D020123:Sirolimus / Q000031:analogs & derivatives*
chemical_list: D020123:Sirolimus